Materialise (MTLS) Q2 2026 Earnings Call Transcript

The market should view this less as a one-quarter beat and more as evidence that the business is migrating toward higher-quality, more defensible revenue. The real winners are the parts of the additive-manufacturing stack tied to regulated, repeatable workflows: MTLS’s software layer, certified aerospace production, and hospital-integrated medical tooling. That shift is a headwind for commoditized prototyping shops and smaller niche service bureaus that depend on discretionary capex cycles; their pricing power gets worse as customers consolidate around vendors that can prove compliance, automation, and throughput.

Near term, the stock’s reaction is likely driven by the guide raise and cash conversion, but the next catalyst is whether CO-AM turns into a measurable attach-rate story rather than a roadmap story. The key risk is that management is already telling us software demand remains soft where budgets depend on grants and reimbursement; if those end markets do not normalize over the next 1-3 quarters, the “subscription transition” may just offset decline rather than create acceleration. Over 6-18 months, sustained margin expansion depends on keeping R&D disciplined; if working capital builds or the hardware mix shifts back toward lower-margin prototype work, the cash narrative will fade quickly.

Consensus may be missing that the most valuable change is portfolio quality, not top-line growth. The stock looks under-owned if investors still frame MTLS as a cyclical 3D-printing proxy; it looks overdone only if they extrapolate a full medical software reacceleration without a recovery in U.S. academic funding and orthopedics reimbursement. Falsifiers: a 2H revenue slowdown, EBIT guidance cut back toward the prior range, or evidence that CO-AM adoption is not translating into higher recurring revenue by the next two quarters.